2/4
04:05 pm
svra
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Medium
Report
Savara Announces Participation in Upcoming Investor Healthcare Conferences
1/27
08:05 am
svra
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
Low
Report
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
1/24
11:38 am
svra
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Medium
Report
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
1/16
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
1/11
09:22 am
svra
With 37% stake, Savara Inc. (NASDAQ:SVRA) seems to have captured institutional investors' interest [Yahoo! Finance]
Low
Report
With 37% stake, Savara Inc. (NASDAQ:SVRA) seems to have captured institutional investors' interest [Yahoo! Finance]
1/8
04:27 pm
svra
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* [Yahoo! Finance]
Low
Report
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* [Yahoo! Finance]
1/8
04:05 pm
svra
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
Low
Report
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
12/23
10:13 am
svra
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at Oppenheimer Holdings, Inc..
Low
Report
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at Oppenheimer Holdings, Inc..
12/23
10:13 am
svra
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at UBS Group AG.
Low
Report
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at UBS Group AG.
12/23
08:42 am
svra
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/23
07:17 am
svra
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/22
09:05 am
svra
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) [Yahoo! Finance]
Medium
Report
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) [Yahoo! Finance]
12/22
08:30 am
svra
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Medium
Report
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
12/18
10:26 am
svra
Savara (NASDAQ:SVRA) had its price target raised by analysts at Wells Fargo & Company from $7.00 to $9.00. They now have an "overweight" rating on the stock.
Low
Report
Savara (NASDAQ:SVRA) had its price target raised by analysts at Wells Fargo & Company from $7.00 to $9.00. They now have an "overweight" rating on the stock.
12/17
08:05 am
svra
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
12/11
08:55 am
svra
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* [Yahoo! Finance]
Low
Report
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* [Yahoo! Finance]
12/11
08:05 am
svra
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
Medium
Report
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
12/2
02:41 pm
svra
Savara Inc. ticks higher amid takeover speculation [Seeking Alpha]
Low
Report
Savara Inc. ticks higher amid takeover speculation [Seeking Alpha]
12/2
08:05 am
svra
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
Low
Report
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
11/20
04:05 pm
svra
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Medium
Report
Savara Announces Participation in Upcoming Investor Healthcare Conferences
11/16
06:36 am
svra
Savara: A High-Risk Opportunity [Seeking Alpha]
Low
Report
Savara: A High-Risk Opportunity [Seeking Alpha]
11/14
12:31 pm
svra
Savara (NASDAQ:SVRA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $8.00 to $9.00. They now have an "outperform" rating on the stock.
Low
Report
Savara (NASDAQ:SVRA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $8.00 to $9.00. They now have an "outperform" rating on the stock.
11/13
10:49 am
svra
Savara (NASDAQ:SVRA) had its price target lowered by analysts at Citizens Jmp from $11.00 to $10.00. They now have a "market outperform" rating on the stock.
Medium
Report
Savara (NASDAQ:SVRA) had its price target lowered by analysts at Citizens Jmp from $11.00 to $10.00. They now have a "market outperform" rating on the stock.
11/12
04:05 pm
svra
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
11/10
09:50 am
svra
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
Low
Report
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm